Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 DiabetesJulio Rosenstock|JAMA|2019Cited by 593
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 DiabetesVanita R. Aroda, Ömür Tabak, Erik Christiansen et al.|Diabetes Care|2019Cited by 465
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 TrialHelena W. Rodbard, Е. О. Филиппова, Julio Rosenstock et al.|Diabetes Care|2019Cited by 442
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trialFilip K. Knop, W. Timothy Garvey, Vanita R. Aroda et al.|The Lancet|2023Cited by 377
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized TrialVanita R. Aroda, Julio Rosenstock, Carol Wysham et al.|Diabetes Care|2016Cited by 254